HTA, medicines cost effectiveness, NICE, Patient Access Scheme, pharma market access, pharma pricing, PPRS, UK drug pricing
0 Comment
UK drug pricing: just how free is free pricing, these days?
drug market access, Drug pricing, NICE, pharma market access, Pharmaceutical Price Regulation Scheme, PPRS, UK drug market
0 Comment
Should there be a different review of NICE as part of a successor PPRS?
Innovation, Leela Barham, life sciences industrial strategy, Life Sciences Sector Deal, Pharmaceutical Price Regulation Scheme, PPRS
0 Comment
Has the PPRS delivered on the aim to support the government’s growth and innovation agenda?
drug market access, Leela Barham, market access, medicines assessment, NHS, NHSE, Pharmaceutical Price Regulation Scheme, PPRS
0 Comment
Has the PPRS delivered on the aim of reducing bureaucracy and duplication?
Leela Barham, NHS, NHSE, Pharmaceutical Price Regulation Scheme, PPRS
0 Comment
Keeping the UK branded medicines bill within affordable limits – has PPRS delivered?
drug market access, Drug pricing, Leela Barham, NHS, Pharmaecutical price regulation scheme, PPRS
0 Comment
PPRS impact: has it kept the branded medicines bill within affordable limits?
Department of Health, DH, Drug pricing, Leela Barham, Pharmaceutical Price Regulation Scheme, PPRS
0 Comment
Has the UK PPRS scheme met its five objectives?
Department of Health, DH, Drug pricing, Health budget, NHS, PPRS, UK pharma
0 Comment
How contributions from the updated PPRS have affected the DH budget for the NHS.
